

**TDMS No.** 95003 - 06

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS  
ABRIDGED) (a)**

**Date Report Requested:** 10/09/2009

**Test Type:** CHRONIC

Methyl trans-styryl ketone

**Time Report Requested:** 14:36:21

**Route:** SKIN APPLICATION

**CAS Number:** 1896-62-4

**First Dose M/F:** 04/26/04 / 04/26/04

**Species/Strain:** MICE/B6C3F1

**Lab:** SRI

F1\_M3

**C Number:** C95003C  
**Lock Date:** 01/29/2007  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 2.1.0

Test Type: CHRONIC

Methyl trans-styryl ketone

Time Report Requested: 14:36:21

Route: SKIN APPLICATION

CAS Number: 1896-62-4

First Dose M/F: 04/26/04 / 04/26/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Accidently Killed		1		
Moribund Sacrifice	4	2	8	5
Natural Death	12	12	7	7
Survivors				
Terminal Sacrifice	34	35	35	38
Animals Examined Microscopically	50	50	50	50

## ALIMENTARY SYSTEM

Gallbladder	(40)	(38)	(44)	(38)
Intestine Large, Cecum	(41)	(46)	(46)	(46)
Carcinoma	1 (2%)			
Intestine Large, Colon	(39)	(43)	(44)	(43)
Intestine Large, Rectum	(41)	(43)	(46)	(46)
Intestine Small, Duodenum	(40)	(42)	(44)	(43)
Carcinoma			1 (2%)	
Intestine Small, Ileum	(40)	(44)	(45)	(43)
Intestine Small, Jejunum	(41)	(42)	(45)	(44)
Adenoma	1 (2%)	2 (5%)		
Carcinoma	1 (2%)	1 (2%)		
Carcinoma, Metastatic, Lung	1 (2%)			
Liver	(50)	(50)	(50)	(49)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Cholangiocarcinoma		1 (2%)		
Hemangiosarcoma	4 (8%)	2 (4%)	1 (2%)	
Hepatoblastoma	1 (2%)	3 (6%)	1 (2%)	
Hepatoblastoma, Multiple			1 (2%)	1 (2%)
Hepatocellular Adenoma	19 (38%)	11 (22%)	13 (26%)	19 (39%)
Hepatocellular Adenoma, Multiple	12 (24%)	18 (36%)	10 (20%)	10 (20%)
Hepatocellular Carcinoma	22 (44%)	14 (28%)	17 (34%)	16 (33%)
Hepatocellular Carcinoma, Multiple	6 (12%)	14 (28%)	13 (26%)	15 (31%)
Hepatocholangiocarcinoma		1 (2%)		1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Methyl trans-styryl ketone

Time Report Requested: 14:36:21

Route: SKIN APPLICATION

CAS Number: 1896-62-4

First Dose M/F: 04/26/04 / 04/26/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
Mesentery	(6)	(12)	(8)	(6)
Carcinoma, Metastatic, Lung	1 (17%)			
Carcinoma, Metastatic, Pancreas		1 (8%)		
Cholangiocarcinoma, Metastatic, Liver		1 (8%)		
Hemangiosarcoma		1 (8%)		
Hepatocellular Carcinoma, Metastatic, Liver		1 (8%)	1 (13%)	
Pancreas	(49)	(50)	(50)	(49)
Cholangiocarcinoma, Metastatic, Liver		1 (2%)		
Acinus, Carcinoma		1 (2%)		
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Hemangioma		1 (2%)		
Hemangiosarcoma		1 (2%)		
Squamous Cell Carcinoma	1 (2%)			
Squamous Cell Papilloma	3 (6%)	2 (4%)	2 (4%)	
Stomach, Glandular	(47)	(49)	(49)	(48)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Hemangiosarcoma		1 (2%)		
Tooth	(1)	(1)	(0)	(0)
<b>CARDIOVASCULAR SYSTEM</b>				
Heart	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (2%)			
Cholangiocarcinoma, Metastatic, Liver		1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Atrium, Hemangiosarcoma	1 (2%)			
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(50)	(50)	(49)
Adenoma	1 (2%)			1 (2%)
Bilateral, Capsule, Adenoma		1 (2%)		
Capsule, Adenoma	5 (10%)	5 (10%)	7 (14%)	7 (14%)
Adrenal Medulla	(49)	(50)	(50)	(49)
Pheochromocytoma Benign		1 (2%)	1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Methyl trans-styryl ketone

Time Report Requested: 14:36:21

Route: SKIN APPLICATION

CAS Number: 1896-62-4

First Dose M/F: 04/26/04 / 04/26/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
Islets, Pancreatic	(50)	(50)	(50)	(49)
Adenoma	2 (4%)	1 (2%)	1 (2%)	5 (10%)
Cholangiocarcinoma, Metastatic, Liver		1 (2%)		
Parathyroid Gland	(48)	(47)	(48)	(45)
Pituitary Gland	(49)	(49)	(50)	(49)
Pars Distalis, Carcinoma				1 (2%)
Thyroid Gland	(50)	(49)	(50)	(49)
C-cell, Carcinoma			1 (2%)	
Follicular Cell, Adenoma	1 (2%)			1 (2%)
<b>GENERAL BODY SYSTEM</b>				
Tissue NOS	(2)	(2)	(2)	(0)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (50%)	
Cholangiocarcinoma, Metastatic, Liver		1 (50%)		
Hemangiosarcoma		1 (50%)		
Hepatocellular Carcinoma, Metastatic, Liver			1 (50%)	
<b>GENITAL SYSTEM</b>				
Epididymis	(50)	(50)	(50)	(50)
Penis	(0)	(0)	(2)	(0)
Preputial Gland	(50)	(50)	(50)	(50)
Prostate	(50)	(50)	(50)	(48)
Seminal Vesicle	(50)	(50)	(50)	(49)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Testes	(50)	(50)	(50)	(50)
Cholangiocarcinoma, Metastatic, Liver		1 (2%)		
Interstitial Cell, Adenoma				1 (2%)
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma, Metastatic, Spleen	1 (2%)			
Lymph Node	(5)	(5)	(4)	(6)
Cholangiocarcinoma, Metastatic, Liver		1 (20%)		
Bronchial, Hepatocholangiocarcinoma,		1 (20%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Methyl trans-styryl ketone

Time Report Requested: 14:36:21

Route: SKIN APPLICATION

CAS Number: 1896-62-4

First Dose M/F: 04/26/04 / 04/26/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
Metastatic, Liver				
Iliac, Cholangiocarcinoma, Metastatic, Liver		1 (20%)		
Lymph Node, Mandibular	(49)	(46)	(50)	(49)
Lymph Node, Mesenteric	(49)	(44)	(49)	(45)
Carcinoma, Metastatic, Intestine Large, Cecum	1 (2%)			
Carcinoma, Metastatic, Pancreas		1 (2%)		
Cholangiocarcinoma, Metastatic, Liver		1 (2%)		
Hemangioma			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver				1 (2%)
Spleen	(48)	(47)	(49)	(49)
Hemangiosarcoma	3 (6%)			1 (2%)
Thymus	(44)	(48)	(46)	(40)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Cholangiocarcinoma, Metastatic, Liver		1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
<b>INTEGUMENTARY SYSTEM</b>				
Mammary Gland	(50)	(50)	(50)	(50)
Skin	(50)	(50)	(50)	(50)
Hemangioma	1 (2%)			
Squamous Cell Papilloma		1 (2%)		
Pinna, Hemangioma				1 (2%)
Subcutaneous Tissue, Fibrosarcoma	1 (2%)			
Subcutaneous Tissue, Hemangioma		1 (2%)		
Subcutaneous Tissue, Hemangiosarcoma	1 (2%)	3 (6%)	1 (2%)	
Subcutaneous Tissue, Hepatocellular Carcinoma, Metastatic, Lung				1 (2%)
Subcutaneous Tissue, Melanoma Benign			1 (2%)	
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(49)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Methyl trans-styryl ketone

Time Report Requested: 14:36:21

Route: SKIN APPLICATION

CAS Number: 1896-62-4

First Dose M/F: 04/26/04 / 04/26/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
Sternum, Hemangiosarcoma, Metastatic, Spleen	1 (2%)			
Skeletal Muscle	(1)	(4)	(1)	(1)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (25%)	1 (100%)	
Cholangiocarcinoma, Metastatic, Liver		1 (25%)		
Hemangiosarcoma	1 (100%)			
Hepatocellular Carcinoma, Metastatic, Liver		1 (25%)		
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Lung	1 (2%)			
Meningioma Benign		1 (2%)		
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	7 (14%)	7 (14%)	4 (8%)	5 (10%)
Alveolar/Bronchiolar Adenoma, Multiple	1 (2%)			3 (6%)
Alveolar/Bronchiolar Carcinoma	6 (12%)	2 (4%)	3 (6%)	2 (4%)
Alveolar/Bronchiolar Carcinoma, Multiple	1 (2%)	1 (2%)	1 (2%)	3 (6%)
Cholangiocarcinoma, Metastatic, Liver		1 (2%)		
Hepatoblastoma, Metastatic, Liver			1 (2%)	1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver	4 (8%)	2 (4%)	6 (12%)	7 (14%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Nose	(50)	(50)	(50)	(50)
Trachea	(50)	(50)	(50)	(50)
<b>SPECIAL SENSES SYSTEM</b>				
Eye	(49)	(48)	(48)	(45)
Harderian Gland	(48)	(50)	(50)	(50)
Adenoma	2 (4%)	7 (14%)	4 (8%)	5 (10%)
Carcinoma	1 (2%)	1 (2%)	2 (4%)	2 (4%)
Bilateral, Adenoma		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Methyl trans-styryl ketone

Time Report Requested: 14:36:21

Route: SKIN APPLICATION

CAS Number: 1896-62-4

First Dose M/F: 04/26/04 / 04/26/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
<b>URINARY SYSTEM</b>				
Kidney	(48)	(49)	(49)	(47)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Carcinoma, Metastatic, Lung	1 (2%)			
Cholangiocarcinoma, Metastatic, Liver		1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver				1 (2%)
Renal Tubule, Adenoma	1 (2%)			1 (2%)
Renal Tubule, Carcinoma				1 (2%)
Urethra	(1)	(0)	(0)	(0)
Urinary Bladder	(49)	(48)	(49)	(48)
<b>SYSTEMIC LESIONS</b>				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma		1 (2%)	1 (2%)	2 (4%)
Lymphoma Malignant	4 (8%)	9 (18%)	8 (16%)	5 (10%)

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Methyl trans-styryl ketone

Time Report Requested: 14:36:21

Route: SKIN APPLICATION

CAS Number: 1896-62-4

First Dose M/F: 04/26/04 / 04/26/04

Species/Strain: MICE/B6C3F1

Lab: SRI

---

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
------------------	---------	----------	----------	----------

---

**Tumor Summary for Males**

<b>Total Animals with Primary Neoplasms (b)</b>	49	49	46	47
<b>Total Primary Neoplasms</b>	111	118	95	110
<b>Total Animals with Benign Neoplasms</b>	37	34	34	39
<b>Total Benign Neoplasms</b>	56	60	44	60
<b>Total Animals with Malignant Neoplasms</b>	37	39	39	41
<b>Total Malignant Neoplasms</b>	55	58	51	50
<b>Total Animals with Metastatic Neoplasms</b>	7	6	8	9
<b>Total Metastatic Neoplasms</b>	13	27	15	12
<b>Total Animals with Malignant Neoplasms Uncertain Primary Site</b>				
<b>Total Animals with Neoplasms Uncertain-Benign or Malignant</b>				
<b>Total Uncertain Neoplasms</b>				

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors



Test Type: CHRONIC

Methyl trans-styryl ketone

Time Report Requested: 14:36:21

Route: SKIN APPLICATION

CAS Number: 1896-62-4

First Dose M/F: 04/26/04 / 04/26/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	6	6	10	7
Natural Death	7	5	9	6
Survivors				
Terminal Sacrifice	37	39	31	37
Animals Examined Microscopically	50	50	50	50
<b>ALIMENTARY SYSTEM</b>				
Gallbladder	(44)	(47)	(40)	(43)
Intestine Large, Cecum	(47)	(49)	(45)	(46)
Carcinoma			1 (2%)	
Intestine Large, Colon	(44)	(47)	(42)	(44)
Intestine Large, Rectum	(45)	(48)	(43)	(44)
Intestine Small, Duodenum	(43)	(47)	(43)	(44)
Adenoma		1 (2%)		
Carcinoma	1 (2%)			
Intestine Small, Ileum	(43)	(45)	(42)	(45)
Intestine Small, Jejunum	(43)	(46)	(42)	(44)
Carcinoma		2 (4%)		
Hemangiosarcoma	1 (2%)			
Liver	(50)	(50)	(50)	(49)
Fibrosarcoma, Metastatic, Uncertain Primary Site		1 (2%)		
Hemangiosarcoma	1 (2%)		1 (2%)	
Hepatocellular Adenoma	9 (18%)	13 (26%)	9 (18%)	10 (20%)
Hepatocellular Adenoma, Multiple	21 (42%)	21 (42%)	28 (56%)	19 (39%)
Hepatocellular Carcinoma	16 (32%)	10 (20%)	12 (24%)	5 (10%)
Hepatocellular Carcinoma, Multiple	7 (14%)	7 (14%)	3 (6%)	3 (6%)
Sarcoma		1 (2%)		
Mesentery	(16)	(22)	(17)	(13)
Fibrosarcoma		1 (5%)		
Hemangiosarcoma				1 (8%)
Hepatocellular Carcinoma, Metastatic, Liver		1 (5%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Methyl trans-styryl ketone

Time Report Requested: 14:36:21

Route: SKIN APPLICATION

CAS Number: 1896-62-4

First Dose M/F: 04/26/04 / 04/26/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
Liposarcoma		1 (5%)		
Pancreas	(50)	(50)	(49)	(47)
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Squamous Cell Papilloma	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Stomach, Glandular	(48)	(48)	(48)	(46)
Fibrosarcoma		1 (2%)		
<b>CARDIOVASCULAR SYSTEM</b>				
Heart	(50)	(50)	(50)	(50)
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(49)	(50)	(50)
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
Capsule, Adenoma			1 (2%)	
Adrenal Medulla	(50)	(49)	(50)	(50)
Pheochromocytoma Benign		1 (2%)	1 (2%)	2 (4%)
Pheochromocytoma Malignant	1 (2%)	2 (4%)	2 (4%)	1 (2%)
Islets, Pancreatic	(50)	(50)	(49)	(47)
Adenoma		1 (2%)	2 (4%)	
Parathyroid Gland	(46)	(48)	(46)	(46)
Pituitary Gland	(47)	(49)	(50)	(46)
Carcinoma			1 (2%)	
Pars Distalis, Adenoma	5 (11%)	5 (10%)	4 (8%)	3 (7%)
Pars Distalis, Carcinoma			1 (2%)	1 (2%)
Pars Intermedia, Adenoma		1 (2%)		
Thyroid Gland	(49)	(50)	(49)	(47)
Follicular Cell, Adenoma			1 (2%)	1 (2%)
Follicular Cell, Carcinoma	1 (2%)		1 (2%)	
<b>GENERAL BODY SYSTEM</b>				
Tissue NOS	(3)	(2)	(4)	(0)
Fibrosarcoma		1 (50%)	1 (25%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Methyl trans-styryl ketone

Time Report Requested: 14:36:21

Route: SKIN APPLICATION

CAS Number: 1896-62-4

First Dose M/F: 04/26/04 / 04/26/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
Fibrosarcoma, Metastatic, Skin			1 (25%)	
Hemangiosarcoma	1 (33%)			
Sarcoma	1 (33%)			
<b>GENITAL SYSTEM</b>				
Clitoral Gland	(48)	(49)	(50)	(46)
Ovary	(49)	(50)	(48)	(50)
Cystadenoma	1 (2%)		2 (4%)	1 (2%)
Fibrosarcoma		1 (2%)		
Sarcoma		1 (2%)		
Teratoma Benign			1 (2%)	
Teratoma Malignant		1 (2%)		
Bilateral, Cystadenoma			1 (2%)	
Uterus	(50)	(50)	(49)	(50)
Carcinoma	1 (2%)			
Hemangiosarcoma	1 (2%)	1 (2%)		
Polyp Stromal	1 (2%)	3 (6%)	1 (2%)	1 (2%)
Sarcoma		1 (2%)		
Vagina	(1)	(2)	(1)	(0)
Liposarcoma	1 (100%)			
Sarcoma, Metastatic, Uncertain Primary Site		1 (50%)		
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)		2 (4%)	
Sarcoma		1 (2%)		
Lymph Node	(13)	(11)	(15)	(14)
Sarcoma, Metastatic, Uncertain Primary Site		1 (9%)		
Iliac, Hepatocellular Carcinoma, Metastatic, Liver	1 (8%)			
Mediastinal, Fibrosarcoma, Metastatic, Skin			1 (7%)	
Lymph Node, Mandibular	(50)	(48)	(46)	(50)
Sarcoma		1 (2%)		
Lymph Node, Mesenteric	(47)	(49)	(45)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Methyl trans-styryl ketone

Time Report Requested: 14:36:21

Route: SKIN APPLICATION

CAS Number: 1896-62-4

First Dose M/F: 04/26/04 / 04/26/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
Fibrosarcoma, Metastatic, Uncertain Primary Site		1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		
Sarcoma		1 (2%)		
Spleen	(49)	(50)	(48)	(48)
Hemangiosarcoma	2 (4%)	1 (2%)	3 (6%)	
Sarcoma		1 (2%)		
Thymus	(50)	(46)	(46)	(48)
<b>INTEGUMENTARY SYSTEM</b>				
Mammary Gland	(50)	(50)	(50)	(50)
Carcinoma	2 (4%)	1 (2%)		
Myoepithelioma				1 (2%)
Skin	(50)	(50)	(50)	(50)
Basal Cell Carcinoma			1 (2%)	
Fibrosarcoma	1 (2%)		3 (6%)	1 (2%)
Melanoma Benign				1 (2%)
Schwannoma Malignant		1 (2%)		
Pinna, Neural Crest Tumor			1 (2%)	
Site Of Application, Mast Cell Tumor Benign	1 (2%)		1 (2%)	
Subcutaneous Tissue, Fibrosarcoma		2 (4%)	1 (2%)	1 (2%)
Subcutaneous Tissue, Hemangiosarcoma	2 (4%)		2 (4%)	
Subcutaneous Tissue, Schwannoma Malignant	1 (2%)			1 (2%)
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(49)	(50)	(50)	(50)
Rib, Hemangiosarcoma			1 (2%)	
Skeletal Muscle	(3)	(2)	(2)	(3)
Fibrosarcoma, Metastatic, Skin	1 (33%)		1 (50%)	
Fibrosarcoma, Metastatic, Uncertain Primary Site		1 (50%)	1 (50%)	
Hemangiosarcoma	1 (33%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Methyl trans-styryl ketone

Time Report Requested: 14:36:21

Route: SKIN APPLICATION

CAS Number: 1896-62-4

First Dose M/F: 04/26/04 / 04/26/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Pituitary Gland				1 (2%)
Peripheral Nerve	(1)	(1)	(0)	(0)
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Adenoma	1 (2%)	1 (2%)	3 (6%)	4 (8%)
Alveolar/Bronchiolar Carcinoma	3 (6%)	3 (6%)	1 (2%)	2 (4%)
Fibrosarcoma, Metastatic, Skin			2 (4%)	
Hemangiosarcoma	1 (2%)			
Hepatocellular Carcinoma, Metastatic, Liver	4 (8%)	4 (8%)	6 (12%)	
Pheochromocytoma Malignant, Metastatic, Adrenal Medulla		1 (2%)		
Sarcoma		1 (2%)		
Nose	(50)	(50)	(50)	(50)
Pleura	(1)	(0)	(0)	(1)
Hemangiosarcoma, Metastatic, Lung	1 (100%)			
<b>SPECIAL SENSES SYSTEM</b>				
Eye	(47)	(50)	(48)	(47)
Harderian Gland	(50)	(50)	(49)	(49)
Adenoma	4 (8%)	4 (8%)	6 (12%)	5 (10%)
Carcinoma		1 (2%)	2 (4%)	1 (2%)
<b>URINARY SYSTEM</b>				
Kidney	(49)	(50)	(48)	(47)
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		
Sarcoma	1 (2%)			
Urinary Bladder	(49)	(50)	(48)	(48)
Leiomyosarcoma			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Methyl trans-styryl ketone

Time Report Requested: 14:36:21

Route: SKIN APPLICATION

CAS Number: 1896-62-4

First Dose M/F: 04/26/04 / 04/26/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
SYSTEMIC LESIONS				
Multiple Organs	* (50)	* (50)	* (50)	* (50)
Histiocytic Sarcoma	1 (2%)	1 (2%)	1 (2%)	5 (10%)
Lymphoma Malignant	20 (40%)	24 (48%)	20 (40%)	25 (50%)

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Methyl trans-styryl ketone

Time Report Requested: 14:36:21

Route: SKIN APPLICATION

CAS Number: 1896-62-4

First Dose M/F: 04/26/04 / 04/26/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG
<b>Tumor Summary for Females</b>				
Total Animals with Primary Neoplasms (b)	48	48	48	47
Total Primary Neoplasms	113	122	125	96
Total Animals with Benign Neoplasms	33	37	42	37
Total Benign Neoplasms	44	52	63	49
Total Animals with Malignant Neoplasms	42	43	39	36
Total Malignant Neoplasms	69	70	61	47
Total Animals with Metastatic Neoplasms	6	7	9	1
Total Metastatic Neoplasms	7	14	13	1
Total Animals with Malignant Neoplasms Uncertain Primary Site		2	1	
Total Animals with Neoplasms Uncertain-Benign or Malignant			1	
Total Uncertain Neoplasms			1	

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors